Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemp seed protein hydrolysate fraction F3 is a bioactive peptide-rich extract derived from the enzymatic hydrolysis of hemp seed (*Cannabis sativa* L.) protein isolate. It is typically produced through a sequential digestion process using pepsin and pancreatin to simulate human gastrointestinal digestion, achieving a degree of hydrolysis of approximately 48%. The resulting hydrolysate is then fractionated using ultrafiltration or chromatography. In a three-fraction separation system, F3 represents the high-molecular-weight component (typically >10 kDa). Preclinical research has identified this specific fraction as possessing the most potent antiproliferative activity among hemp protein derivatives, demonstrating significant growth inhibition in cancer cell lines such as Caco-2 (colorectal cancer) and THP-1 (leukemia). While lower molecular weight fractions exhibit higher antioxidant capacity, F3 is primarily characterized by its potential chemoprotective and antineoplastic properties, making it a subject of interest for functional food and nutraceutical applications in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hemp seed protein hydrolysate fraction F3.